Unicycive Therapeutics Inc
UNCY
Company Profile
Business description
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Contact
4300 El Camino Real
Suite 210
Los AltosCA94022
USAT: +1 650 351-4495
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,642.90 | 5.10 | 0.06% |
| CAC 40 | 7,779.72 | 8.38 | -0.11% |
| DAX 40 | 23,933.23 | 104.96 | -0.44% |
| Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
| FTSE 100 | 8,716.45 | 9.56 | -0.11% |
| HKSE | 23,224.40 | 348.98 | -1.48% |
| NASDAQ | 19,175.87 | 74.93 | 0.39% |
| Nikkei 225 | 37,936.65 | 496.33 | -1.29% |
| NZX 50 Index | 12,332.94 | 51.63 | 0.42% |
| S&P 500 | 5,912.17 | 23.62 | 0.40% |
| S&P/ASX 200 | 8,417.30 | 7.50 | 0.09% |
| SSE Composite Index | 3,353.07 | 10.38 | -0.31% |